Passage Bio Inc (PASG) - Total Assets
Based on the latest financial reports, Passage Bio Inc (PASG) holds total assets worth $36.46 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Passage Bio Inc - Total Assets Trend (2018–2025)
This chart illustrates how Passage Bio Inc's total assets have evolved over time, based on quarterly financial data. Also see PASG market cap overview for the company's overall valuation and market capitalisation.
Passage Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Passage Bio Inc's total assets of $36.46 Million consist of 76.7% current assets and 23.3% non-current assets. Review total liabilities of Passage Bio Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 74.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Passage Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Passage Bio Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Passage Bio Inc's current assets represent 76.7% of total assets in 2025, a decrease from 99.8% in 2018.
- Cash Position: Cash and equivalents constituted 74.4% of total assets in 2025, up from 74.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Passage Bio Inc Competitors by Total Assets
Key competitors of Passage Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Passage Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.73 | 3.74 | 13.40 |
| Quick Ratio | 1.73 | 3.74 | 13.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $14.64 Million | $48.84 Million | $387.59 Million |
Passage Bio Inc - Advanced Valuation Insights
This section examines the relationship between Passage Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.20 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | -39.2% |
| Total Assets | $62.28 Million |
| Market Capitalization | $14.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values Passage Bio Inc's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Passage Bio Inc's assets decreased by 39.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Passage Bio Inc (2018–2025)
The table below shows the annual total assets of Passage Bio Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $62.28 Million | -39.19% |
| 2024-12-31 | $102.41 Million | -31.97% |
| 2023-12-31 | $150.54 Million | -38.19% |
| 2022-12-31 | $243.55 Million | -31.41% |
| 2021-12-31 | $355.08 Million | +8.25% |
| 2020-12-31 | $328.01 Million | +83.64% |
| 2019-12-31 | $178.61 Million | +433.79% |
| 2018-12-31 | $33.46 Million | -- |
About Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops P… Read more